Q-omics provides the consensus-scored ZNF793 profile across patient tissues and cancer cell-line models. ZNF793 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZNF793 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ZNF793 RNA expression shows 20,248 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, HNSC, and THYM as cancer lineages where ZNF793 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF793 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF793 survival associations across molecular data types. ZNF793 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF793 RNA expression–survival associations across cancer types. High ZNF793 expression shows unfavorable associations in LGG and LUSC, but favorable associations in UCS, PAAD, BLCA and ACC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for ZNF793 RNA expression.
This table summarizes ZNF793 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF793. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF793 shows lower tumor expression in HNSC, THCA, KICH, COAD and KIRC and higher tumor expression in LUAD. The HNSC box plot shows higher ZNF793 RNA expression in normal versus tumor tissue (log2 FC = −0.285, t-test p = .002).
This table shows molecular features associated with ZNF793 in patient tissues and cancer cell lines. In patient samples, ZNF793 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF793 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Lymphoma.
